Mumbai: Pharma company Wanbury Ltd has clocked a 146% rise in consolidated turnover at Rs90.73 crore for the quarter ended 30 September as against Rs36.84 crore in the year-ago period.
The company’s profit after tax rose 150% to Rs8.89 crore, against Rs3.57 crore in the corresponding period last fiscal, a release issued here today said.
During the quarter, Wanbury completed the acquisition of the generic division of Industrial Farmaceutica Cantabria SA Spain.
The company also allotted 2,06,674 equity shares of Rs10 each at a premium of Rs128.43 per share, upon conversion of 50 bonds of foreign currency convertible A bonds during the quarter.
Wanbury is the world’s largest producer of both Metformin, a diabetes management product and Salsalate, an anti-inflammatory drug.